HRTX - NASDAQ

Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Melissa Jarel, Executive Director. Please go ahead.

Thank you, operator and good morning, everyone. Thank you for joining us on the Heron Therapeutics conference call this morning to discuss the company's financial results for the quarter ended September 30, 2024. With me today from Heron are Craig Collard, Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy and Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call. Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs and future performance, all of which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. And with that, I would now like to turn the call over to Craig Collard, Chief Executive Officer of Heron.

Thanks, Melissa. Good morning, everyone and welcome to the Heron Therapeutics third quarter 2024 earnings call. Today, we are pleased to update you on our latest achievements for the third quarter which includes a narrowing of our financial guidance, including net revenue, adjusted operating expenses and adjusted EBITDA. We have also given a Q4 2024 net revenue guidance range of $37 million to $43 million based on the early success achieved already in Q4. We also received FDA approval of the Vial Access Needle or VAN, on September 24 and we have been included in the final version of the NOPAIN Act which goes into effect in January of 2025. Last, our partnership with CrossLink continues to progress and we are now beginning to see the positive impact that this could have for

Thank you, Craig. Our product gross profit for the 3 months ended September 30, 2024, was $23.4 million or 71% which increased from 42% for the same period in 2023. This was primarily due to the fact that the current quarter did not see the significant inventory write-offs we experienced in the comparable quarter of 2023. Year-to-date, our product gross profit was $75.1 million or 73%, an increase from 41% for the same period in 2023. SG&A expenses for the 3 and 9 months ended September 30, 2024, were $23.3 million and $77.3 million, respectively, compared to $28.8 million and $106.7 million, respectively, in the same period in 2023. The decrease was primarily related to decreases in personnel and related costs due to the reductions in force in prior years as well as improved cost efficiencies among all departments. Research and development expenses were $4.5 million and $13.5 million for the 3 and 9 months ended September 30, 2024, compared to $9.3 million and $31.3 million in the comparable periods in 2023. The decrease was primarily related to decreases in personnel and related costs due to the reductions in force implemented in previous years as well as decrease in development activities. As noted in the 10-Q, the condensed consolidated statements of operations and comprehensive loss as of September 30, 2023, reflects reclassification of certain expenses from research and development to general and administrative expenses to align with the function of the expenses incurred. This resulted in no change to total operating expenses. The net loss was $4.8 million for the 3 months ended September 30, 2024 and $17.2 million for the 9 months ended September 30, 2024, compared to $25 million and $99.8 million, respectively, for the comparable periods in 2023. Cash and short-term investments at September 30, 2024, was $70.9 million. The overall year-to-date cash burn for the business was less than $10 million. Year-to-date, we incurred inventory write-offs of $2.4 million. Unlike last year's write-offs, current year write-offs were not related to inventory management. In addition, we also recorded asset impairment write-offs of $2.1 million, primarily related to projects no longer part of the company's forward-looking strategy. As you will see on the slide, if you had excluded depreciation, stock-based compensation, inventory write-offs and the asset impairment write-offs, our adjusted EBITDA results would have been a positive $1.4 million operating income which represents a substantial turnaround in the financial management of the business. As a result of our year-to-date cost efficiency measures and overall performance, we are revising our guidance for the rest of the year. We are narrowing our net revenue range from our Q2 guidance of $138 million to $158 million to a revised range of $140 million to $146 million net revenue. We are narrowing our Q2 guidance for adjusted operating expenses which excludes stock compensation, depreciation and fixed asset write-offs from our previous range of $107 million to $111 million to a revised range of $101 million to $105 million. Lastly, we are narrowing our Q2 adjusted EBITDA guidance range which excludes inventory write-offs, stock compensation, depreciation and fixed asset write-offs of negative $10 million to positive $3 million to a revised range of positive $2 million to positive $5 million. And now, we'd like to open the call for any questions.

And our first question for today comes from the line of Kelly Shi from Jefferies.

This is Jose [ph] for Kelly. Now that VAN is approved, how should we think about the uptake curve moving forward? And what is your anticipation of the customer mix between existing

Yes, thanks for the question. So currently, with the VAN, we anticipate having the VAN in the market in customers' hands by the first week of December. And the plan with that is to really start off with a few accounts and to get folks comfortable with that to make sure that there's no issue in launching the product and so forth. We're going to places before that are very comfortable with the product. Beyond that, we're then going to accounts where we've had an issue. And what I mean by that is, an account that maybe have walked away before due to the preparation of the product. And so again, we have a number of accounts that fall into that category. So I think you have that. And then obviously, with any new accounts that we have that CrossLink has brought on, we've been talking about the fact that this device is coming out and will improve the prep time. So we're extremely excited about the potential of this because it really does solve an issue that has been out there for quite a while and with the prep time of the product and also really addressing [indiscernible].

And our next question comes from the line of Carl Byrnes from Northland Capital Markets.

My questions on VAN have been answered. So I wanted to kind of circle back to CINVANTI. I'm wondering if you could comment a little bit on the nuances in the third quarter in terms of the sequential decline and then your outlook for the fourth quarter, given the guidance that you provided.

Yes. Thanks, Carl. As we've said before, CINVANTI is in an extremely competitive market. It's obviously a lot of things going with ASP reimbursement and just new folks coming into the market and so forth. And so we've historically maintained around 28% share. But again, you have these quarterly fluctuations where you lose an account, win an account and that type of thing. And so we did lose a fairly large account in Q3 which obviously showed up in net revenues. But we wanted to -- one of the reasons we gave the guidance we did for fourth quarter is that I make the comment in my when I was talking about CINVANTI and really the whole entire product portfolio is that we now have this sort of One Heron approach to things. And what I really mean by that is that we're selling across the product portfolio. And we've never had that quite that focus before with so many of our commercial-facing people. And so what we've really been able to take advantage of outside of going after new accounts is on the 340B side of the hospital with CINVANTI. And so we're already seeing quite a bit of uptake in that in Q4. And so we expect CINVANTI to bounce back strong and again, perform into next year.

[Operator Instructions] Our next question comes from the line of Serge Belanger from Needham.

I guess the first one on 3Q results. OpEx also took a tick down from second quarter. Just wondering if this is a function of lower sales in the third quarter or it's a new base level we should think of going forward? And then, Craig, going back to the litigation around CINVANTI, do you still expect a court decision next month or by the end of the year?

Yes. No, thanks, Serge. Good to hear from you. I think -- I want to restate your question. I think the first question was on OpEx. Look, we are continuing to manage OpEx as efficiently as we can. The lower that falling a little bit in Q3. Again, I think it's just been us managing that. I think it will sort of level out in this sort of frame that we're in now. But -- and I'll let Ira speak to that as well. But I want to come to the litigation for a second and speak to that and then I'll come back to Ira. Regarding the litigation, look, we still feel extremely strong about the case. We had closing arguments in August and really believe that ultimately, we'll win this when this is all said and done which this has to be resolved by December 14 of this year. So we could literally get a decision any moment. But again, we anticipate winning the case and moving on in the patent extending out to 2035.

Serge, the OpEx for Q3, yes, it did but I wouldn't necessarily see it as a new baseline. It's basically a blend of Q2 and Q3. It was just timing in Q3 on a couple that resulted in lower expenses. So it's not -- that is not the new baseline going forward.

Okay. Maybe one last one. As we think of NOPAIN for 2025, how much of a tailwind can this be? I think you have pretty comprehensive coverage right now in the ASC setting, so and HOPDs. Just curious what changes? And can it really be -- I guess, how much of a tailwind can it be for the

Are you referring to NOPAIN? I'm sorry, I missed the first part of that.

The NOPAIN Act, how much of a tailwind...

Yes. No, look, I think, again, with CrossLink with VAN and now NOPAIN, I think it's going to be a tremendous help to us. I mean we do have reimbursement now but one of the issues we've really suffered from for quite a while is just awareness. And I think the fact that we're mentioned in the NOPAIN Act that's being talked about a lot. We're now talking about opioid abuse and so forth. And I think having us in that conversation and the fact that we are the longest-acting pain relief product out there, I think, is going to provide significant awareness and is going to create a significant tailwind. So we see it as really a big plus for us going forward.

And our next question comes from the line of Brandon Folkes from Rodman & Renshaw.

I just want to follow-up on the guidance. So maybe when we're talking about the sequential revenue from 3Q to 4Q, can you just elaborate a little bit further about the CINVANTI bounce back that you're referring to versus the VAN uptake for

Yes. Thanks, Brandon. Good to hear from you. Regarding -- I'll start with CINVANTI. Again, CINVANTI was no more than just an account loss in Q3. And so we've been able to win a few other accounts in Q4. And then what we've -- as we begin to promote this product across the portfolio and this has been going on for a few months. So it wasn't just in Q4. But again, we picked up some business in the hospital and have really seen an uptake and I would say, a bounce back to what quarterly revenues looked like prior to Q3. And so we really feel that, that can continue into '25 and we may even gain from where we were before. So that's where CINVANTI sits. And then obviously, it's about managing ASP which we've historically done fairly well. So if we can maintain price and grow in these accounts. We think CINVANTI can continue to perform as we move forward. But I think the main way that I would look at CINVANTI too is more of a foundational business for us. It's allowing us, again, sort of the cash cow, if you will, to fund what we're trying to do on the acute side with

Our next question is a follow-up from the line of Carl Byrnes from Northland Capital Markets.

I'm wondering if you can give us a bit of an update on the development of the Prefilled Syringe.

Thanks, Carl. Bill Forbes is here in the room with me and I'll turn it over to him.

Yes, we continue to progress the Prefilled Syringe program. I mentioned earlier that sterilization and stability were the challenges associated with that. We've made some great progress in the last quarter along those lines. We have had a slight delay because of machine parts and being back ordered but we're moving through that as well. So overall, the program is progressing as expected and we're very hopeful for it because we think it's going to be an advancement even beyond what the VAN is going to give us. Prefilled Syringes, obviously, is going to be the gold standard. The approval date, by the way, we're targeting approval at the very end of 2026, first quarter 2027.

This does conclude the question-and-answer session of today's program. I'd now like to hand the program back to management for any further remarks.

No, we just want to thank everyone for the questions today and we appreciate you joining the call. And we look forward to speaking to everyone next quarter.